肺癌p53基因突变与临床病理关系的研究  

Study between p53 gene mutations of human lung cancer and clinic pathologic relation

作　　者：王岳松[1] 蔓新新[1] 纪树国[1] 蔡庆[1] 姜建东[1] 胡益云[1] 

机构地区：[1]北京空军总医院

出　　处：《临床与实验病理学杂志》1997年第2期98-100,共3页Chinese Journal of Clinical and Experimental Pathology

摘　　要：目的：探讨肺癌ｐ５３基因突变与临床之关系；方法：采用ＰＣＲ－限制性片段长度多态性分析法（ＰＣＲ－ＲＦＬＰ）检测４７例人肺癌ｐ５３基因２４９位密码子点突变；结果：非小细胞肺癌（ＮＳＣＬＳ）ｐ５３基因２４９位密码子突变率２４．２４％，小细胞肺癌（ＳＣＬＣ）突变率为０（０／１４），ｐ５３基因２４９位密码子点突变与肺癌分期、组织分化、吸烟无关（Ｐ＞０．０５），与ＮＳＣＬＣ淋巴结转移有关（Ｐ＜０．０５）；结论：ｐ５３基因２４９位密码子突变是ＮＳＣＬＣ突变热点，是评估ＮＳＣＬＣ预后因素之一。Purpose To study the relation p53 gene 249 coden mutation of human lung cancer and clinic; Methods p53 gene 249 codon mutations in 47 cases of human lung cancer were detected by PCR RFLP; Results p53 gene 249 codon mutation rates in NSCLC and SCLC was 24 24% (8/33), 0(0/14) respectively. There didnt appear to be an association between this mutation and staging, histological differentiation, smoking in lung cancer ( P >0 05). p53 gene 249 codon mutation correlated with metastatic lymph nodes in NSCLC ( P <0 05); Conclusions p53 gene 249 codon mutation is a mutation hotpoint in NSCLC, also is one of the prognostic factors for NSCLC.

关 键 词：P53基因 点突变 肺肿瘤 基因突变 

分 类 号：R734.202[医药卫生—肿瘤] R730.231.3[医药卫生—临床医学]